TY  - CONF

T1  - 2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid

JO  - BJU INTERNATIONAL

PY  - 2013/04/01

AU  - Kueppers F

AU  - Fizazi K

AU  - Brown J

AU  - Carducci M

AU  - Shore N

AU  - Sieber P

AU  - Karsh L

AU  - Wei R

AU  - Goessl C

ED  - 

VL  - 111

SP  - 91

EP  - 92

Y2  - 2024/12/21

ER  -